XNCR · Xencor, Inc.

Summary

Xencor disclosed final Phase 1 results for XmAb942 showing favorable PK, tolerability, and immunogenicity supporting 12-week SC dosing in ongoing Phase 2b XENITH-UC study, plus preclinical data for XmAb412 with FIH study planned for 3Q26.

Key takeaways

• XmAb942 Phase 1 final results: well tolerated, 74.1-day half-life supports 12-week SC maintenance dosing in XENITH-UC.
• XmAb942 projected >99% TL1A inhibition in 86% patients during induction vs 31-40% for first-gen anti-TL1A.
• XENITH-UC Phase 2b enrolling ~220 UC patients, blinded interim ~YE26, primary endpoint results 2H27.
• XmAb412 preclinical: sub-picomolar affinities, >20-day half-life in NHP, FIH healthy volunteer study 3Q26.
• Conference call held May 5, 2026, discussing DDW presentations on XmAb942 and XmAb412 data.